First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association...

por Gridelli, C., Peters, S., Mok, T., Forde, P.M., Reck, M., Attili, I., de Marinis, F.
Publicado 2021

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

por Reck, M., Barlesi, F., Crinò, L., Henschke, C. I., Isla, D., Stiebeler, S., Spigel, D. R.
Publicado 2012

Morphological reassessment and molecular phylogenetic analyses of Amauroderma s.lat. raised new perspectives in the generic classification of the Ganodermataceae family

por Costa-Rezende, D.H., Robledo, G.L., Góes-Neto, A., Reck, M.A., Crespo, E., Drechsler-Santos, E.R.
Publicado 2017

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (...

por Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C.
Publicado 2010

Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

por Arriola, E., Paredes-Lario, A., García-Gomez, R., Diz-Tain, P., Constenla, M., García-Girón, C., Márquez, G., Reck, M., López-Vivanco, G.
Publicado 2018

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation...

por Garon, E.B., Reck, M., Nishio, K., Heymach, J.V., Nishio, M., Novello, S., Paz-Ares, L., Popat, S., Aix, S. Ponce, Graham, H., Butts, B.D., Visseren-Grul, C., Nakagawa, K.
Publicado 2023

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

por McKeage, M J, Von Pawel, J, Reck, M, Jameson, M B, Rosenthal, M A, Sullivan, R, Gibbs, D, Mainwaring, P N, Serke, M, Lafitte, J-J, Chouaid, C, Freitag, L, Quoix, E
Publicado 2008

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

por Watermann, I., Schmitt, B., Stellmacher, F., Müller, J., Gaber, R., Kugler, Ch., Reinmuth, N., Huber, R. M., Thomas, M., Zabel, P., Rabe, K. F., Jonigk, D., Warth, A., Vollmer, E., Reck, M., Goldmann, T.
Publicado 2015

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

por Tan, E.-H., Ramlau, R., Pluzanska, A., Kuo, H.-P., Reck, M., Milanowski, J., Au, J. S.-K., Felip, E., Yang, P.-C., Damyanov, D., Orlov, S., Akimov, M., Delmar, P., Essioux, L., Hillenbach, C., Klughammer, B., McLoughlin, P., Baselga, J.
Publicado 2010

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

por Kirchner, M., Kluck, K., Brandt, R., Volckmar, A.-L., Penzel, R., Kazdal, D., Endris, V., Neumann, O., Seker-Cin, H., Goldschmid, H., Glade, J., Allgäuer, M., Kriegsmann, M., Winter, H., Muley, T., Perner, S., Frost, N., Reck, M., Fröhling, S., Schirmacher, P., Thomas, M., Budczies, J., Christopoulos, P., Stenzinger, A.
Publicado 2021

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

por Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Publicado 2021

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year...

por Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Publicado 2021

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

por Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, J D, Bunn Jr, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H, Thatcher, N
Publicado 2018

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

por Mountzios, G., Samantas, E., Senghas, K., Zervas, E., Krisam, J., Samitas, K., Bozorgmehr, F., Kuon, J., Agelaki, S., Baka, S., Athanasiadis, I., Gaissmaier, L., Elshiaty, M., Daniello, L., Christopoulou, A., Pentheroudakis, G., Lianos, E., Linardou, H., Kriegsmann, K., Kosmidis, P., El Shafie, R., Kriegsmann, M., Psyrri, A., Andreadis, C., Fountzilas, E., Heussel, C.-P., Herth, F.J., Winter, H., Emmanouilides, C., Oikonomopoulos, G., Meister, M., Muley, T., Bischoff, H., Saridaki, Z., Razis, E., Perdikouri, E.-I., Stenzinger, A., Boukovinas, I., Reck, M., Syrigos, K., Thomas, M., Christopoulos, P.
Publicado 2021